Efficacy and safety of bimekizumab in real-world psoriasis management: data from patients who are biologic-naive vs. biologic-experienced
Clinical and Experimental Dermatology · 18.09.2024 · 49 (10) · 1186-1189
DOI: 10.1093/ced/llae147 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Dermatology, online erschienen am 24.04.2024. Verfasst von Matteo Megna und 5 weiteren Autor:innen. Beteiligte Einrichtung: Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy. Hauptthemen laut MEDLINE: Psoriasis, Severity of Illness Index, Antibodies, Monoclonal, Humanized, Quality of Life. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 8 Literaturangaben.
Abstract (Originalsprache)
Background
Bimekizumab is the latest monoclonal antibody approved for the management of moderate-to-severe plaque psoriasis. Currently, data investigating its use in real-world settings are limited.
Objectives
To assess the efficacy and safety of bimekizumab, also comparing patients who are biologic-naive vs. biologic-experienced.
Methods
A short-term (16 weeks) real-world monocentric prospective study was undertaken.
Results
Globally, 56 patients were included. At baseline, mean Psoriasis Activity Severity Index (PASI) and Dermatology Life Quality Index (DLQI) were 16.9 (SD 7.8) and 22.6 (SD 5.9), respectively. A ≥ 75%/≥ 90%/100% reduction in PASI (PASI 75/90/100) were reached by 77% (43/56)/50% (28/56)/43% (43/56) of patients at week 4 and by 88% (49/56)/82% (46/56)/70% (39/56) of patients at week 16. In our cohort of 56 people, 29 (52%) patients were biologic-naive whereas 27 (48%) were biologic-experienced. At baseline, both PASI and DLQI were significantly higher in the biologic-naive group compared with the biologic-experienced group [PASI 19.4 (SD 7.7) vs. 14.2 (SD 7.0), P < 0.05; DLQI: 25.3 (SD 4.5) vs. 19.7 (SD 6.0), P < 0.001]. Although not significant, a higher percentage of patients in the biologic-naive group compared with the biologic-experienced group reached PASI 75 (79% vs. 63%, P = 0.18), PASI 90 (62% vs. 44%, P = 0.19) and PASI 100 (48% vs. 37%, P = 0.40) at week 4. However, the percentage of PASI 75/90/100 response were similar between the two groups at week 16. Regarding safety, three candidiasis (5%) and one (2%) eczematous reaction were reported, without differences between the two groups. Finally, two (4%) bimekizumab discontinuation because of treatment failure and three (5%) for AEs were collected.
Conclusions
Our study confirmed the efficacy and safety of bimekizumab, suggesting that the previous failure of biologics does not seem to affect its therapeutic effectiveness.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
ORCID-Profile: Angelo Ruggiero, Fabrizio Martora, Luca Potestio
Zitieren
APA
Megna, M., Ruggiero, A., Torta, G., Martora, F., Bianco, M., & Potestio, L. (2024). Efficacy and safety of bimekizumab in real-world psoriasis management: data from patients who are biologic-naive vs. biologic-experienced. Clinical and Experimental Dermatology, 49(10), 1186-1189. https://doi.org/10.1093/ced/llae147
Vancouver
Megna M, Ruggiero A, Torta G, Martora F, Bianco M, Potestio L. Efficacy and safety of bimekizumab in real-world psoriasis management: data from patients who are biologic-naive vs. biologic-experienced. Clinical and Experimental Dermatology. 2024;49(10):1186-1189. doi:10.1093/ced/llae147
BibTeX
@article{Megna2024,
author = {Megna, Matteo and Ruggiero, Angelo and Torta, Ginevra and Martora, Fabrizio and Bianco, Mariateresa and Potestio, Luca},
title = {Efficacy and safety of bimekizumab in real-world psoriasis management: data from patients who are biologic-naive vs. biologic-experienced},
journal = {Clinical and Experimental Dermatology},
year = {2024},
volume = {49},
number = {10},
pages = {1186--1189},
doi = {10.1093/ced/llae147}
}
EUVIMED